BIOTTS AMONG THE CEBIOFORUM WINNERS 2019

We are pleased to inform you that our portfolio company BIOTTS was among the winners of the CBF Award competition start-up category in which the most innovative companies from the BioTech🔝 sector participated. The competition’s task is to reveal biotechnology companies and people from Central Europe that excel in innovation, through implementation of ambitious research and development projects. The aim of the competition is to select real leaders in the biotechnology sector of our Region, and one of the most important criteria is to be assessed in potential commercialisation of developed projects.

BIOTTS is a biotechnology company owner of proprietary, patented transdermal system (TTS) technology for the penetration of medicinal substances. 💊 It serves as a transporter for active natural or synthetic substances into the deeper tissues of the skin. The carrier can be used in the treatment of many diseases entities, including: atopic skin, skin inflammation, acne, prostate cancer, bacterial and viral infections of the skin, burns, difficult to heal wounds.

Congratulations to the BIOTTS  team! 👏

BIOCELTIX WINNER IN THE INDUSTRY OF LIFE SCIENCE DURING START-UP CHALLENGE 2019

On Tuesday (14th May) during the European Start-Up Days – event accompanying the 11th European Economic Congress in Katowice – prizes were distributed in the Start-Up Challenge competition.

18 start-ups have been selected from the record number of 300 entries to present their innovations. We are proud of Bioceltix, which have won in the category of medicine, health, medical technologies, pharmacy, biotechnology. The jury awarded Bioceltix for ambitious clinical research plan, developed business model and the ability to scale solutions. The team’s competences were also appreciated. Bioceltix is ​​one of the global pioneers implementing animal-safe and business-scaled technology of the therapeutic use of animal, allogenic (one donor – many recipients) stem cells.

We warmly congratulate the team Bioceltix 👏 We keep our fingers crossed for effective commercialization!

At the same time, we invite you to listen to the interview given by the president of Bioceltix for radio TOK FM – dr Łukasz Bzdzion. 🎧

 

THE POLES BRINGING A REVOLUTION IN VETERINARY – MONEY.PL ABOUT AMBITIOUS BIOCELTIX PLANS

 

We encourage you to read the article from Money.pl portal, which presents development plans for our portfolio company – Bioceltix.  The team of scientists led by Łukasz Bzdzion is working on innovative biological drugs used in the treatment of common diseases in animals that use immunomodulatory properties of mesenchymal stem cells (MSC).

 Bioceltix is ​​one of the first companies in the world planning to go through the full registration path in EMA for a veterinary biological medicine that uses MSC as an active substance. The registration needs to happen in order to place the drug on the market. In connection with this, the Wrocław startup conducts an individual dialogue with the Agency as part of scientific advice and meets a number of its stringent requirements.

 “The market for veterinary biological drugs is still in its infancy – only two years ago, the first biotechnology medicine was registered in EMA.  We intend to change it “- declares the president of Bioceltix, Łukasz Bzdzion.

Leonarto has been supporting Bioceltix in development since 2017, when the Fund’s investment took place in this extremely innovative and ground-breaking project.

Read the article

Photo – Bioceltix SA

FOREIGN LABORATORIES AUTOMATISED BY BIOAVLEE – PULS BIZNESU ABOUT OUR PORTFOLIO COMPANY

 

 

 

 

 

 

 

We encourage you to read the Business Pulse article, which presents the achievements of Bioavlee in terms of the current development and sale of products, but also presents company further plans that wants to primarily conquer foreign markets with its solutions. “The Polish market is not yet well-off enough for companies to invest in innovative equipment. Money goes to more urgent needs, and the labor cost of native laboratory technicians is still much lower than in Western Europe, “comments Michał Wronecki, President of Bioavlee. We also recommend the commentary of Magdalena Surowiec – the Managing Partner of our Fund who, is working on a daily basis with biotechnology companies under the Leonarto Fund wings, and is meeting the challenges and problems of startups in this very demanding industry.

NESTMEDIC WITH SUCCESS ON THE FINISH MARKET!

Nestmedic S.A. will deliver the Pregnabit system to the University Hospital in Helsinki (HUS). The order for the Pregnabit teleCTG devices and the license are the result of a successful pilot project carried out at HUS. The first full implementation on the Finnish market opens a new chapter in the expansion of the Pregnabit system in foreign markets.

“This is a very important project in the implementation of the foreign market expansion strategy for the hashtag#Pregnabit system. Our solution has been appreciated by a specialist hospital in a very demanding market. This is also the outcome of our successful cooperation with a business partner in Finland, Steripolar Finland (Head Office). With this project we are starting a new chapter in the development of our company on foreign markets”, comments  Sławomir Bartoszcze, Director of International Expansion at Nestmedic S.A.

Well done Nestmedic! Keep doing!

Contact us